- CD19: The use of anti-CD19 CAR T cell therapies given immediately after autologous hematopoietic cell transplantation (AHCT) has been explored, with the idea that CD19 may be expressed on a tumor propagating myeloma stem cell compartment that could be putatively eradicated (132–134). Here, CD19 is linked to plasma cell myeloma.